On June 28, 2019, Mette Kirstine Agger notified Trevi Therapeutics, Inc., of her decision to resign from her position as a member of Company's Board of Directors, effective as of June 30, 2019. Ms. Agger's resignation was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. On June 28, 2019, the Board, acting in accordance with the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael Heffernan as a member of the Audit Committee of the Board, effective as of June 30, 2019, to fill the vacancy created by Ms. Agger's resignation.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.
TREVI THERAPEUTICS, INC. 
